Radiation therapy firm Accuray posted a 5% increase in revenue in its fiscal third quarter, but costs associated with its pending acquisition of TomoTherapy pushed the firm into the red.
For the period (end-March 31), Accuray reported revenue of $54.7 million, up from the $51.9 million posted during the third quarter of fiscal 2010. The company had a net loss of $1.2 million, compared with net income of $2.3 million a year ago.
Accuray attributed the net loss to approximately $2.6 million in costs associated with the TomoTherapy deal. The company shipped 13 CyberKnife systems and installed four during the quarter, increasing its worldwide installed base to 226 systems.
